Basel, Switzerland
Basel, Switzerland

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, ranking number one in sales among the world-wide industry in 2013.Novartis manufactures such drugs as clozapine , diclofenac , carbamazepine , valsartan and imatinib mesylate . Additional agents include cyclosporin , letrozole , methylphenidate , terbinafine , and others.In 1996 Ciba-Geigy merged with Sandoz, with the pharmaceutical and agrochemical divisions of both staying together to form Novartis. Other Ciba-Geigy and Sandoz businesses were sold off, or, like Ciba Specialty Chemicals, were spun off as independent companies. The Sandoz brand disappeared for 3 years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Novartis divested its agrochemical and genetically modified crops business in 2000 with the spinout of Syngenta in partnership with AstraZeneca, which also divested its agrochemical business.Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations the International Federation of Pharmaceutical Manufacturers and Associations , and the Pharmaceutical Research and Manufacturers of America . Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Method for washing, with a water-based system, reusable molds for making silicone hydrogel contact lenses. The water-based washing system comprises a solvo-surfactant which is an alkyl (propylene glycol)nether wherein alkyl is a linear alkyl group having 2 to 5 carbon atoms and n is the integer 1, 2 or 3. The water-based system of the invention can effectively wash away silicone-containing components and other components of a lens formulation left behind on the molding surfaces of a reusable mold, after removing a silicone hydrogel contact lens cast molded in the reusable mold.


The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.


Patent
Novartis | Date: 2017-04-12

The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.


Patent
Novartis | Date: 2017-05-17

An apparatus for laser assisted eye treatment comprises: a laser device configured to provide focused laser radiation and having an adapter coupling port; an adapter module including first and second sub-modules, the first sub-module configured to detachably couple to the laser device at the adapter coupling port and having a contact surface for an eye, the second sub-module including an eye suction ring portion having a ring axis, wherein the second sub-module delimits at least one suction space, and the adapter module includes a vacuum inlet port in association with each of the at least one suction chamber, wherein the adapter module includes an evacuation path system configured to establish a vacuum communication connection between each of the at least one suction space and the associated vacuum inlet port, wherein the vacuum inlet port is provided at the first sub-module and the evacuation path system extends from the first sub-module to the second sub-module.


Patent
Novartis | Date: 2017-09-27

The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.


Patent
Novartis and University of Chicago | Date: 2017-09-27

The here described invention discloses a combination of a top and bottom loop binder library using the CD and the FG loops of a number of FnIII domains (FnIII) (e.g., FnIII7, FnIII10 and FnIII14) together with the surface exposed residues of the beta-sheet. The invention also pertains to a method of forming a library of FnIII domain polypeptides useful in screening for the presence of one or more polypeptides having a selected binding or enzymatic activity.


The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.


Patent
Novartis | Date: 2017-09-27

An ophthalmic laser processing apparatus comprises: a laser device configured to output a pulsed laser beam towards an eye, the laser beam having a beam focus; an image capturing device positioned to capture an image of the eye and configured to provide image data; and a control device configured to detect eye movement based on the image data and to control the beam focus temporally and spatially based on a predetermined eye processing pattern and the detected eye movement. The apparatus further comprises a visualization device controlled by the control device to output a visualization of a graphical illustration. The graphical illustration represents at least one of (a) a value of an eye parameter determined on the basis of the image data in relation to each of a plurality of different time points or time intervals; (b) a frequency distribution of a value of an eye parameter determined on the basis of the image data in relation to each of a plurality of different time points or time intervals; and (c) a range of values of a pupil diameter determined on the basis of the image data.


Weers J.,Novartis
Advanced Drug Delivery Reviews | Year: 2015

Inhaled antibiotics dramatically improve targeting of drug to the site of respiratory infections, while simultaneously minimizing systemic exposure and associated toxicity. The high local concentrations of antibiotic may enable more effective treatment of multi-drug resistant pathogens. This review explores barriers to effective treatment with inhaled antibiotics. In addition, potential opportunities for improvements in treatment are reviewed. © 2014 Elsevier B.V.


Sellers W.R.,Novartis
Cell | Year: 2011

In the era of next-generation sequencing, there are significant challenges to harnessing cancer genome information to develop novel therapies. Key research thrusts in both academia and industry will speed this transition, and lessons learned for cancer will more broadly shape the process for genetic contributions to the therapy of disease more broadly. © 2011 Elsevier Inc.

Loading Novartis collaborators
Loading Novartis collaborators